TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data

The evolution of cancer genomes within a single tumor creates mixed cell populations with divergent somatic mutational landscapes. Inference of tumor subpopulations has been disproportionately focused on the assessment of somatic point mutations, whereas computational methods targeting evolutionary dynamics of copy number alterations (CNA) and loss of heterozygosity (LOH) in whole-genome sequencing data remain underdeveloped. We present a novel probabilistic model, TITAN, to infer CNA and LOH events while accounting for mixtures of cell populations, thereby estimating the proportion of cells harboring each event. We evaluate TITAN on idealized mixtures, simulating clonal populations from whole-genome sequences taken from genomically heterogeneous ovarian tumor sites collected from the same patient. In addition, we show in 23 whole genomes of breast tumors that the inference of CNA and LOH using TITAN critically informs population structure and the nature of the evolving cancer genome. Finally, we experimentally validated subclonal predictions using fluorescence in situ hybridization (FISH) and single-cell sequencing from an ovarian cancer patient sample, thereby recapitulating the key modeling assumptions of TITAN.

[1]  Nicholas B. Larson,et al.  PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data , 2013, Bioinform..

[2]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[3]  P. Maxwell,et al.  Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. , 2012, Cancer research.

[4]  Michalis Vazirgiannis,et al.  Clustering validity checking methods: part II , 2002, SGMD.

[5]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[6]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[7]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[8]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[9]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[10]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[11]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[12]  Christopher Yau,et al.  OncoSNP-SEQ: a statistical approach for the identification of somatic copy number alterations from next-generation sequencing of cancer genomes , 2013, Bioinform..

[13]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[14]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[15]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[16]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[17]  R. Olson,et al.  Abstract 5675: Potential use of proteosome pathway inhibitor (bortezomib) in combination with anthracyclines to treat multiple myeloma and pancreatic cancer , 2012 .

[18]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[19]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[20]  J. Salk Clonal evolution in cancer , 2010 .

[21]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[22]  P. Campbell,et al.  Single-cell mutational profiling and clonal phylogeny in cancer , 2013, Genome research.

[23]  Tatiana Popova,et al.  Supplementary Methods , 2012, Acta Neuropsychiatrica.

[24]  Ali Bashashati,et al.  Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.

[25]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[26]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[27]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[28]  Lovelace J. Luquette,et al.  Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes , 2013, Cell.

[29]  Mark D. Johnson,et al.  Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion , 2011, Proceedings of the National Academy of Sciences.

[30]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[31]  John Quackenbush,et al.  Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome , 2012, Clinical Cancer Research.

[32]  Oliver Sieber,et al.  A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data , 2010, Genome Biology.

[33]  Benjamin J. Raphael,et al.  THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data , 2013, Genome Biology.

[34]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[35]  A. Bashashati,et al.  Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer , 2012, Genome research.

[36]  Christopher J. R. Illingworth,et al.  High-Definition Reconstruction of Clonal Composition in Cancer , 2014, Cell reports.

[37]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[38]  M. Gerstung,et al.  Reliable detection of subclonal single-nucleotide variants in tumour cell populations , 2012, Nature Communications.

[39]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .